Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
NCT02112838 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fostamatinib 150 mg
- DRUG Fostamatinib 100 mg
Study Locations (20)
Other
- Medical University Vienna, Nephrology — Vienna
- Queen Mary Hospital — Hong Kong
- China Medical University Hospital — Taichung
- School of Medicine, Chang Gung University, Chang Gung Memorial Hospital — Taoyuan District
- Addenbrookes Hospital — Cambridge
- Cardiff University — Cardiff
- Leicester General Hospital — Leicester
- Royal Free Hospital — London
- Hammersmith Hospital — London
- Freeman Hospital — Newcastle upon Tyne
California
- Stanford University Medical — Palo Alto
Georgia
- Nephrology Associates PC, University Hospital, Professional Center 1 — Augusta
Ohio
- Ohio State University — Columbus
Tennessee
- Southeast Renal Research Institute — Chattanooga
Styria
- Medical University of Graz — Graz
Baden-Wurtemberberg
- Medical University of Heidelberg — Heidelberg
Bavaria
- Klinikum der Universität München — Munich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2014-10 |
| Est. Completion | 2018-11-12 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02112838
The ClinicalTrials.gov registry entry for NCT02112838 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rigel Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with IGA Nephropathy appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02112838 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Other, California, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02112838 about?
NCT02112838 is a clinical study titled "Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy". The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy
What is the current status of trial NCT02112838?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2014-10. Estimated completion is 2018-11-12.
What conditions does trial NCT02112838 study?
This clinical trial studies the following conditions: IGA Nephropathy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02112838?
The interventions under investigation include: Placebo (DRUG), Fostamatinib 150 mg (DRUG), Fostamatinib 100 mg (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02112838?
This trial is sponsored by Rigel Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02112838 being conducted?
This trial has 20 study locations across California, Georgia, Ohio, Tennessee, Styria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.